Elanco has completed its acquisition of Novartis Animal Health it announced today. The move, which was first announced in April 2014, will create a new global leader in animal health allowing the business to focus on delivering increased value and innovation to the industry.

The move follows Elanco’s acquisition of Lohmann Animal Health earlier in 2014 and will mean the company will offer a comprehensive portfolio of 300 brands encompassing therapeutics, vaccines, parasiticides, antimicrobials, surgical, enzymes, food safety and more.